Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 2/20 | 0.35 |
| ▸ | RARA | P10276 | 4/20 | 0.34 |
| ▸ | RARB | P10826 | 4/20 | 0.34 |
| ▸ | RARG | P13631 | 4/20 | 0.34 |
| ▸ | RXRA | P19793 | 2/20 | 0.34 |
| ▸ | HNF4A | P41235 | 1/20 | 0.34 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6670543 | 0.83 | MAP3K14 (0.43) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL6668122 | 0.81 | MAP3K14 (0.39) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL6664711 | 0.78 | MAP3K14 (0.37) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL7713129 | 0.77 | RARB (0.36) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL6665875 | 0.76 | THRB (0.38) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL3260843 | 0.76 | CYP3A4 (0.50) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL9006914 | 0.74 | RARB (0.35) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL9185941 | 0.72 | RARB (0.44) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL9006928 | 0.70 | RARA (0.33) | MAP3K14RARARARBRARGRXRA | |
| SCHEMBL6610206 | 0.70 | CYP26A1 (0.34) | MAP3K14RARARARBRARGRXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7655699-B1 | Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors | EISAI INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | EISAI INC. | 2006-05-18 | — | — | US | disclosed |
| US-6610883-B1 | Such as 3-methyl-5-(2-(2-(2,6,6-trimethylcyclohexen-1-yl)-ethenyl)phenyl)-2,4 -pentadienoic acid | LIGAND PHARMACEUTICALS, INC. | 2003-08-26 | — | — | US | disclosed |
| US-6320074-B1 | IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, AUTOIMMUNE DISEASES, FATTY ACID METABOLISM, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, OR PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS INCORPORATED | 2001-11-20 | — | — | US | disclosed |
| EP-0637297-B1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 2000-08-23 | — | — | EP | disclosed |
| US-6043279-A | COMPOUNDS USED FOR IN VIVO MODULATION OF LIPID METABOLISM, SKIN-RELATED PROCESSES, MALIGNANT CELL DEVELOPMENT, PREMALIGNANT LESIONS, PROGRAMMED CELL DEATH | LIGAND PHARMACEUTICALS, INCORPORATED (US) | 2000-03-28 | — | — | US | disclosed |
| EP-0983991-A2 | Compounds having selectivity for retinoid x receptors | LIGAND PHARMACEUTICALS, INC. (US) | 2000-03-08 | — | — | EP | disclosed |
| EP-0678086-B1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-12-08 | — | — | EP | disclosed |
| US-5962731-A | MODIFY LIPID METABOLISM; SKIN DISORDERS,; AUTOIMMUNE DISEASES; FATTY ACID METABOLISM; ANTITUMOR AGENTS | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1999-10-05 | — | — | US | disclosed |
| EP-0678087-B1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARM INC (US) | 1999-03-17 | — | — | EP | disclosed |
| US-5780676-A | BICYCLIC BENZYL, PYRIDINYL, THIOPHENE, FURANYL, PYRROLE, AND POLYENOIC ACID DERIVATIVES | LIGAND PHARMACEUTICALS INCORPORATED (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0678087-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0678086-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS, INC. (US) | 1995-10-25 | — | — | EP | disclosed |
| EP-0637297-A4 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS. | LIGAND PHARM INC (US) | 1995-09-20 | — | — | EP | disclosed |
| WO-1995004036-A1 | COMPOUNDS HAVING SELECTIVE ACTIVITY FOR RETINOID X RECEPTORS, AND MEANS FOR MODULATION OF PROCESSES MEDIATED BY RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1995-02-09 | — | — | WO | disclosed |
| WO-1994015902-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
| WO-1994015901-A1 | COMPOUNDS HAVING SELECTIVITY FOR RETINOID X RECEPTORS | LIGAND PHARMACEUTICALS INC. (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106072-A1 | Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors | RXRB, RXRA, RXRG | MAP3K14 3089/4885RARA 6/4885RARB 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.